

# ***Basingstoke, Southampton and Winchester***

## ***District Prescribing Committee (DPC)***

**Recommendations of the meeting of 11<sup>th</sup> October 2016**

### **Supported or limited support e.g. Specialist recommendation**

- **Evolocumab (Repatha®) and Alirocumab (Praluent®)** for the treatment of primary hypercholesterolaemia and mixed dyslipidaemia-The DPC supports the availability locally of these products in line with the NICE technology appraisals: Discussions are underway with local specialists to agree a pathway to support the identification of appropriate patients. The current recommendation is that these products should be classified as 'Red' - i.e.prescribing responsibility should remain with the specialist.
- **Wound formulary** – The revision of this guideline was approved, there will be a structured roll out with education sessions across the DPC area.
- **Hampshire Infant feeding guidelines** - These were approved for use and are available on the guidelines section of the West Hampshire CCG website <http://www.westhampshireccg.nhs.uk/downloads/categories/medicines/guidance>
- **Ulipristal acetate (Esmya®) tablets** – the DPC supported its use for the intermittent treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age. Current evidence is for four treatment courses and until further data becomes available, the committee would suggest that the number of treatment courses is limited to a maximum of four.
- **Dymista®** nasal spray suspension is a prescription-only combination of a potent, long-acting antihistamine (azelastine hydrochloride) with a corticosteroid (fluticasone propionate) for dual symptom control of allergic rhinitis. The DPC supported its use in select patients with Severe Rhinitis who have not responded to other therapies as per [BSACI Guidelines for Allergic and Non-Allergic Rhinitis](#) (e.g. oral antihistamine ± nasal corticosteroid – current formulary options include mometasone and fluticasone furoate).
- **Ganciclovir eye gel** – supported for use in place of aciclovir eye ointment (when long term supply problems)
- **Omeprazole oral solution** (unlicensed special) – supported for use within paediatrics
- **Alliance Calcium Syrup** (nutritional supplement) – supported for use within paediatrics as an alternative to Calcium Sandoz which has been discontinued.

### **Not supported**

- **Alendronic acid effervescent tablets (Binosto®)** - the DPC did not support the routine use of this locally as it offers no clinical benefit over current options( tablets and oral solution) and would be at greater cost.

### **Other Information / Reminders**

#### **The DPC has advised the following changes to RAG status**

- **Ferric Maltol (Feracru®)**- This oral preparation for iron deficiency anaemia in patients with inflammatory bowel disease is now classed as Amber to allow GPs to prescribe the remainder of the treatment course once initiated by a specialist.
- **Amiodarone** - this drug has been reclassified from Green to Amber for safety reasons.
- **Degarelix Injection** for the treatment of advanced hormone-dependent prostate cancer in adults with spinal metastases.- Following the publication of NICE TA 404 this has been reclassified from Red to Amber.
- **Fosfomycin sachets**- a licensed product is now available at a less expensive price. In order to obtain the licensed product it must be prescribed as Monuril 3g sachets, Fosfomycin sachets have been reclassified from Amber to Green but must only be prescribed following sensitivities. NOTE: Fosfomycin capsules are unlicensed and non-formulary.
- **Midazolam** – this is now classified as Green for use in palliative care. Remains red for all other indications.

**Summarised on behalf of the District Prescribing Committee - Andrea White (Southampton City CCG)  
12/10/16**